FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2571038480> ?p ?o ?g. }

• W2571038480 endingPage "S1318" @default.
• W2571038480 startingPage "S1317" @default.
• W2571038480 abstract "The use of immunotherapy for the whole Non-Small Cell Lung Cancer (NSCLC) population, is like an untargeted shooting. So trying to discover predictive factors to response still represents the key to the problem. We retrospectively analyzed a cohort of patients (pts) treated with Nivolumab, in the attempt to correlate clinical and molecular features with response. 69 heavily pretreated advanced NSCLCs (16 squamous/53 adenocarcinomas) were retrospectively evaluated for response to Nivolumab. Pts’ samples from a subgroup of responders (14/17 pts, 82%), were further analyzed for PD-L1/PD-1 expression by immunoistochemistry (IHC), and for TILs density. We used rabbit monoclonal antibodies anti PD-L1 [clone E1L3N] for tumor cell expression (0-3, negative-intense) and mouse monoclonal antibody anti PD-1 [clone EH33] for TILs. Clinico-pathologic characteristics: mostly smoker males (81%), PS 0-1 (85%), EGFR+ 7%, K-RAS+ 23%. Overall response rate was 25% (2% complete response and 23% partial response), stable disease 30%, progressive disease 41%. Median progression free survival (PFS) and overall survival (OS) for the entire cohort were 2.9 and 8.3 months (mo) respectively. 1 and 2-y OS rates were both 44% (95% CI, 29-58). Pts with EGFR + NSCLC showed a significantly lower median OS with respect to the wild type cohort (4.5 vs NR; p < 0.005) as well as pts with brain metastases (4.1 vs NR), while a trend toward improvement in PFS for K-RAS+ was seen. A subgroup analysis according to the time to progression to prior chemotherapy regimen (< 3 mo versus > 6 mo), confirmed a poorer survival for those with rapid spread of disease. Among laboratory tests, a better outcome for those who developed G2 leucopenia was demostrated (OS 8.3 vs 5.0 mo). Severe drug-related adverse events occurred in only 5.7% of pts. PD-L1, PD-1, TIL expression for 14/17 pts with OR, were as follows: PD-L1 > 5% 6/14 pts (43%); PD-1 2/14 (14%); focal TILs presence 7/14 (50%). Nivolumab confirms activity in NSCLC with durable responses and acceptable safety profile. Of note, 44% of our patients were alive at 2 years. No predictive role emerged in our small cohort, according PD-L1, PD-1 and TILs expression, for those obtaining a tumor response. Interactions among alternative factors such as smoking habit, mutational status, time to progression, bone marrow toxicities (ie leucopenia), may have more powerful association with response and clinical outcome. Updated clinical activity and biomarker analysis will be presented." @default.
• W2571038480 created "2017-01-13" @default.
• W2571038480 creator A5008403882 @default.
• W2571038480 creator A5011655650 @default.
• W2571038480 creator A5012893447 @default.
• W2571038480 creator A5021264126 @default.
• W2571038480 creator A5030450694 @default.
• W2571038480 creator A5034761732 @default.
• W2571038480 creator A5035764851 @default.
• W2571038480 creator A5052032389 @default.
• W2571038480 creator A5062180939 @default.
• W2571038480 creator A5064515996 @default.
• W2571038480 creator A5078588212 @default.
• W2571038480 creator A5084408786 @default.
• W2571038480 creator A5089948036 @default.
• W2571038480 date "2017-01-01" @default.
• W2571038480 modified "2023-10-16" @default.
• W2571038480 title "P3.02c-068 Immunotherapy against Non-Small Cell Lung Cancer (NSCLC): Looking for Predictive Factors to Avoid an Untargeted Shooting" @default.
• W2571038480 doi "https://doi.org/10.1016/j.jtho.2016.11.1863" @default.
• W2571038480 hasPublicationYear "2017" @default.
• W2571038480 type Work @default.
• W2571038480 sameAs 2571038480 @default.
• W2571038480 citedByCount "0" @default.
• W2571038480 crossrefType "journal-article" @default.
• W2571038480 hasAuthorship W2571038480A5008403882 @default.
• W2571038480 hasAuthorship W2571038480A5011655650 @default.
• W2571038480 hasAuthorship W2571038480A5012893447 @default.
• W2571038480 hasAuthorship W2571038480A5021264126 @default.
• W2571038480 hasAuthorship W2571038480A5030450694 @default.
• W2571038480 hasAuthorship W2571038480A5034761732 @default.
• W2571038480 hasAuthorship W2571038480A5035764851 @default.
• W2571038480 hasAuthorship W2571038480A5052032389 @default.
• W2571038480 hasAuthorship W2571038480A5062180939 @default.
• W2571038480 hasAuthorship W2571038480A5064515996 @default.
• W2571038480 hasAuthorship W2571038480A5078588212 @default.
• W2571038480 hasAuthorship W2571038480A5084408786 @default.
• W2571038480 hasAuthorship W2571038480A5089948036 @default.
• W2571038480 hasBestOaLocation W25710384801 @default.
• W2571038480 hasConcept C121608353 @default.
• W2571038480 hasConcept C126322002 @default.
• W2571038480 hasConcept C143998085 @default.
• W2571038480 hasConcept C159654299 @default.
• W2571038480 hasConcept C203014093 @default.
• W2571038480 hasConcept C2776256026 @default.
• W2571038480 hasConcept C2776694085 @default.
• W2571038480 hasConcept C2777701055 @default.
• W2571038480 hasConcept C2780030458 @default.
• W2571038480 hasConcept C2780739268 @default.
• W2571038480 hasConcept C2908647359 @default.
• W2571038480 hasConcept C542903549 @default.
• W2571038480 hasConcept C54355233 @default.
• W2571038480 hasConcept C552990157 @default.
• W2571038480 hasConcept C71924100 @default.
• W2571038480 hasConcept C72563966 @default.
• W2571038480 hasConcept C81089528 @default.
• W2571038480 hasConcept C86803240 @default.
• W2571038480 hasConcept C99454951 @default.
• W2571038480 hasConceptScore W2571038480C121608353 @default.
• W2571038480 hasConceptScore W2571038480C126322002 @default.
• W2571038480 hasConceptScore W2571038480C143998085 @default.
• W2571038480 hasConceptScore W2571038480C159654299 @default.
• W2571038480 hasConceptScore W2571038480C203014093 @default.
• W2571038480 hasConceptScore W2571038480C2776256026 @default.
• W2571038480 hasConceptScore W2571038480C2776694085 @default.
• W2571038480 hasConceptScore W2571038480C2777701055 @default.
• W2571038480 hasConceptScore W2571038480C2780030458 @default.
• W2571038480 hasConceptScore W2571038480C2780739268 @default.
• W2571038480 hasConceptScore W2571038480C2908647359 @default.
• W2571038480 hasConceptScore W2571038480C542903549 @default.
• W2571038480 hasConceptScore W2571038480C54355233 @default.
• W2571038480 hasConceptScore W2571038480C552990157 @default.
• W2571038480 hasConceptScore W2571038480C71924100 @default.
• W2571038480 hasConceptScore W2571038480C72563966 @default.
• W2571038480 hasConceptScore W2571038480C81089528 @default.
• W2571038480 hasConceptScore W2571038480C86803240 @default.
• W2571038480 hasConceptScore W2571038480C99454951 @default.
• W2571038480 hasIssue "1" @default.
• W2571038480 hasLocation W25710384801 @default.
• W2571038480 hasOpenAccess W2571038480 @default.
• W2571038480 hasPrimaryLocation W25710384801 @default.
• W2571038480 hasRelatedWork W2069496741 @default.
• W2571038480 hasRelatedWork W2544577077 @default.
• W2571038480 hasRelatedWork W2767114511 @default.
• W2571038480 hasRelatedWork W2904759734 @default.
• W2571038480 hasRelatedWork W2972926806 @default.
• W2571038480 hasRelatedWork W3029010559 @default.
• W2571038480 hasRelatedWork W3097428643 @default.
• W2571038480 hasRelatedWork W3137670083 @default.
• W2571038480 hasRelatedWork W3175383630 @default.
• W2571038480 hasRelatedWork W3215044659 @default.
• W2571038480 hasVolume "12" @default.
• W2571038480 isParatext "false" @default.
• W2571038480 isRetracted "false" @default.
• W2571038480 magId "2571038480" @default.
• W2571038480 workType "article" @default.